Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Medical Case Reports
Published in: Journal of Medical Case Reports 1/2007

Open Access 01-12-2007 | Case report

Fatal miliary Coccidioidomycosis in a patient receiving infliximab therapy: a case report

Authors: Mark P Rogan, Karl Thomas

Published in: Journal of Medical Case Reports | Issue 1/2007

Login to get access

Abstract

A 78-year-old white male from Iowa in the United States of America receiving the anti- tumor necrois factor (TNF) agent infliximab therapy for rheumatoid arthritis developed a cheek ulcer which failed to respond to empiric antibiotic therapy. He subsequently presented with progressive respiratory failure from miliary coccidioidomycosis which proved fatal. The patient vacationed in Arizona 6 months previously and likely contracted the organism there as Iowa is not an endemic area for coccidioidomycosis. Respiratory failure from miliary infiltration is an uncommon presentation of coccidioidomycosis. Physicians should be aware of the importance of travel history and potential for life-threatening coccidioidomycosis in patients receiving tumor necrosis factor inhibitors.
Appendix
Available only for authorised users
Literature
1.
Booth AD, Jayne DR, Kharbanda RK, McEniery CM, Mackenzie IS, Brown J, Wilkinson IB: Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation. 2004, 109 (14): 1718-1723. 10.1161/01.CIR.0000124720.18538.DD.CrossRefPubMed
2.
Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, Albera C, Brutsche M, Davis G, Donohue JF, Muller-Quernheim J, Schlenker-Herceg R, Flavin S, Lo KH, Oemar B, Barnathan ES: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006, 174 (7): 795-802. 10.1164/rccm.200603-402OC.CrossRefPubMed
3.
Desai SB, Furst DE: Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006, 20 (4): 757-790. 10.1016/j.berh.2006.06.002.CrossRefPubMed
4.
Chang JT, Lichtenstein GR: Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2006, 3 (4): 220-228. 10.1038/ncpgasthep0447.CrossRefPubMed
5.
Saubolle MA, McKellar PP, Sussland D: Epidemiologic, Clinical and Diagnostic Aspects of Coccidioidomycosis. J Clin Microbiol. 2006
6.
7.
DiCaudo DJ: Coccidioidomycosis: a review and update. J Am Acad Dermatol. 2006, 55 (6): 929-42; quiz 943-5. 10.1016/j.jaad.2006.04.039.CrossRefPubMed
8.
Blair JE, Logan JL: Coccidioidomycosis in solid organ transplantation. Clin Infect Dis. 2001, 33 (9): 1536-1544. 10.1086/323463.CrossRefPubMed
9.
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Jama. 2006, 295 (19): 2275-2285. 10.1001/jama.295.19.2275.CrossRefPubMed
10.
Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, Tesser J, Posever J, Miller M, Araujo J, Kageyama DM, Berry M, Karl L, Yung CM: Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum. 2004, 50 (6): 1959-1966. 10.1002/art.20454.CrossRefPubMed
Metadata
Title
Fatal miliary Coccidioidomycosis in a patient receiving infliximab therapy: a case report
Authors
Mark P Rogan
Karl Thomas
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2007
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/1752-1947-1-79

Other articles of this Issue 1/2007

Journal of Medical Case Reports 1/2007 Go to the issue

Case report

2-methylbutyryl-CoA dehydrogenase deficiency associated with autism and mental retardation: a case report

Case report

Fulminant Clostridium Septicum myonecrosis in well controlled diabetes: a case report

Case report

Ocular pathology of uncommon hematologic malignancies: a case series

Case report

Marathon related death due to brainstem herniation in rehydration-related hyponatraemia: a case report

Case report

Acute pancreatitis related to therapeutic dosing with colchicine: a case report

Case report

Traumatic avulsion of kidney and spleen into the chest through a ruptured diaphragm in a young worker: a case report